NBCA Announces Endorsement of Inari Medical DEFIANCE Trial [Yahoo! Finance]
Inari Medical, Inc. (NARI)
Company Research
Source: Yahoo! Finance
Oct. 15, 2024 "The vast majority of DVT survivors in the NBCA community were treated with the current standard of care, anticoagulation, and too many have developed the debilitating symptoms of post-thrombotic syndrome (PTS) with swollen legs, difficulty walking, skin changes and poorly healing open wounds," said NBCA President and Board Chair, Leslie Lake . "Mechanical thrombectomy procedures that remove clot using technologies like ClotTriever may reduce the risk of PTS in some DVT patients. NBCA commends Inari Medical for investing in DEFIANCE, a much-needed landmark trial which has the potential to impact future guidelines for patients." The DEFIANCE trial will enroll up to 300 patients at up to 60 global sites. The trial's primary endpoint will be a composite of: 1) treatment failure or therapy escalation rates, and 2) severity of PTS assessed at the 6-month follow-up. The study's rigorous design will ensure that the results contribute to a better understanding of how these
Show less
Read more
Impact Snapshot
Event Time:
NARI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NARI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NARI alerts
High impacting Inari Medical, Inc. news events
Weekly update
A roundup of the hottest topics
NARI
News
- Inside a $400 billion bet on the brain-computer interface revolution [Yahoo! Finance Canada]Yahoo! Finance Canada
- Inside a $400 billion bet on the brain-computer interface revolution [Yahoo! Finance]Yahoo! Finance
- Is Inari Medical (NARI) Trading at an Attractive Valuation? [Yahoo! Finance]Yahoo! Finance
- Inari Medical to Participate in the Jefferies London Healthcare ConferenceGlobeNewswire
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Truist Financial Co. from $46.00 to $50.00. They now have a "hold" rating on the stock.MarketBeat
NARI
Earnings
- 10/28/24 - Miss
NARI
Sec Filings
- 11/22/24 - Form 4
- 11/20/24 - Form 4
- 11/18/24 - Form 3
- NARI's page on the SEC website